Evidence map›Paper›PMID 28725704›Full record

ReviewNPJ Parkinson's disease2016

Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future.

K Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, Philipp Loehrer, Anna Sauerbier, Per Odin, Peter Jenner

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Implications of dopaminergic medication withdrawal in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.Frontiers in cellular and infection microbiology · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

K Ray ChaudhuriNational Parkinson Foundation International Centre of Excellence, Department of Neurology, King's College Hospital, London, UK.
Mubasher A QamarNational Parkinson Foundation International Centre of Excellence, Department of Neurology, King's College Hospital, London, UK.ORCID 0000-0002-4105-5097
Thadshani RajahNational Parkinson Foundation International Centre of Excellence, Department of Neurology, King's College Hospital, London, UK.
Philipp LoehrerNational Parkinson Foundation International Centre of Excellence, Department of Neurology, King's College Hospital, London, UK.
Anna SauerbierNational Parkinson Foundation International Centre of Excellence, Department of Neurology, King's College Hospital, London, UK.
Per OdinDepartment of Neurology, Lund University, Skane University Hospital, Lund, Sweden.
Peter JennerNeurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysfunction of the gastrointestinal tract has now been recognized to affect all stages of Parkinson's disease (PD). The consequences lead to problems with absorption of oral medication, erratic treatment response, as well as silent aspiration, which is one of the key risk factors in developing pneumonia. The issue is further complicated by other gut abnormalities, such as small intestinal bacterial overgrowth (SIBO) and an altered gut microbiota, which occur in PD with variable frequency. Clinically, these gastrointestinal abnormalities might be associated with symptoms such as nausea, early-morning "off", and frequent motor and non-motor fluctuations. Therefore, non-oral therapies that avoid the gastrointestinal system seem a rational option to overcome the problems of oral therapies in PD. Hence, several non-oral strategies have now been actively investigated and developed. The transdermal rotigotine patch, infusion therapies with apomorphine, intrajejunal levodopa, and the apomorphine pen strategy are currently in clinical use with a few others in development. In this review, we discuss and summarize the most recent developments in this field with a focus on non-oral dopaminergic strategies (excluding surgical interventions such as deep brain stimulation) in development or to be licensed for management of PD.

Identifiers

PMID28725704
PMCPMC5516582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.